KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) EBIT Margin (2016 - 2025)

Edwards Lifesciences has reported EBIT Margin over the past 17 years, most recently at 9.63% for Q4 2025.

  • Quarterly results put EBIT Margin at 9.63% for Q4 2025, down 1293.0% from a year ago — trailing twelve months through Dec 2025 was 20.84% (down 451.0% YoY), and the annual figure for FY2025 was 20.84%, down 451.0%.
  • EBIT Margin for Q4 2025 was 9.63% at Edwards Lifesciences, down from 19.77% in the prior quarter.
  • Over the last five years, EBIT Margin for EW hit a ceiling of 45.99% in Q4 2022 and a floor of 9.63% in Q4 2025.
  • Median EBIT Margin over the past 5 years was 28.05% (2021), compared with a mean of 28.32%.
  • Biggest five-year swings in EBIT Margin: soared 5774bps in 2021 and later crashed -1860bps in 2023.
  • Edwards Lifesciences' EBIT Margin stood at 28.16% in 2021, then surged by 63bps to 45.99% in 2022, then crashed by -40bps to 27.38% in 2023, then dropped by -18bps to 22.56% in 2024, then tumbled by -57bps to 9.63% in 2025.
  • The last three reported values for EBIT Margin were 9.63% (Q4 2025), 19.77% (Q3 2025), and 26.84% (Q2 2025) per Business Quant data.